Published in Clin Pharmacol Ther on April 01, 1978
The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol (1988) 1.16
Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. Br J Clin Pharmacol (1988) 0.94
A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. Br J Pharmacol (1995) 0.81
Biphasic effects of intra-accumbens histamine administration on spontaneous motor activity in the rat; a role for central histamine receptors. Br J Pharmacol (1988) 0.80
Relationship between sedation and pupillary function: comparison of diazepam and diphenhydramine. Br J Clin Pharmacol (2006) 0.76
The time course of action of three differing doses of noberastine, a novel H1-receptor antagonist, on histamine-induced skin wheals and the relationship to plasma drug concentrations in normal human volunteers. Br J Clin Pharmacol (1993) 0.75
Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ (1989) 4.76
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (1980) 2.85
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol (1966) 2.29
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol (1979) 2.00
Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Reaction between S-nitrosothiols and thiols: generation of nitroxyl (HNO) and subsequent chemistry. Biochemistry (1998) 1.83
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol (1984) 1.66
Pharmacokinetics of methotrexate. Clin Pharmacol Ther (1973) 1.55
Plasma digoxin concentrations in patients on admission to hospital. Br Heart J (1974) 1.46
Structure elucidation of dinucleotides by mass spectrometry. Biochem Biophys Res Commun (1968) 1.40
Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay. Clin Chem (1983) 1.38
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31
Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology (1993) 1.30
Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol (1974) 1.28
Absorption of orally given digoxin preparations. JAMA (1972) 1.27
Effects of tobacco and non-tobacco cigarette smoking on endothelium and platelets. Clin Pharmacol Ther (1985) 1.26
The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet (1977) 1.25
Variability in prescription drug utilization: issues for research. CMAJ (1996) 1.24
Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res (1974) 1.22
Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol (1974) 1.21
Quinidine-rifampin interaction. N Engl J Med (1981) 1.14
Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci U S A (2000) 1.14
Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice. Life Sci (1976) 1.14
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Measurement of partial agonist activity of pindolol. Clin Pharmacol Ther (1981) 1.13
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
Cigarette smoking--induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med (1985) 1.11
Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11
Phenytoin-theophylline interaction. N Engl J Med (1982) 1.10
Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci (1978) 1.09
Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res (1979) 1.09
Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology (1988) 1.08
Cardiac dose-response relationships of oral and intravenous pindolol. Br J Clin Pharmacol (1982) 1.08
Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent. Life Sci (1977) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med (1972) 1.04
Relationships between heart rate and PR interval during physiological and pharmacological interventions. Br J Clin Pharmacol (1987) 1.03
An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit (1983) 1.03
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Grapefruit juice--felodipine interaction in the elderly. Clin Pharmacol Ther (2000) 1.01
Severe coughing during captopril and enalapril therapy. CMAJ (1986) 1.01
Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res (1979) 1.00
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (1972) 1.00
Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther (1985) 1.00
Differences in P-450 cytochromes from livers of rats treated with phenobarbital and with 3-methylcholanthrene. J Biol Chem (1973) 0.99
Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet (1978) 0.99
A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med (1984) 0.97
Tolerance and cardiovascular effects of single dose felodipine/beta-blocker combinations in healthy subjects. J Cardiovasc Pharmacol (1987) 0.97
Prescription writing by generic name and drug cost. J Chronic Dis (1967) 0.96
Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther (1977) 0.95
Drug interactions with warfarin. Arch Intern Med (1968) 0.95
A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol (1970) 0.95
Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol (1984) 0.95
Lack of effect of aspirin on cigarette smoke-induced increase in circulating endothelial cells. Haemostasis (1987) 0.94
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Drug interactions. Pharmacol Physicians (1970) 0.93
Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther (1969) 0.93
A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke (1985) 0.93
Increased venous alpha-adrenoceptor responsiveness in patients with reflex sympathetic dystrophy. Ann Intern Med (1993) 0.93
Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res (1974) 0.92
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol (1987) 0.92
Induction of drug metabolism. 3. Further information of a new P-450 hemoprotein after treatment of rats with 3-methylcholanthrene. Mol Pharmacol (1969) 0.91
Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. Clin Pharmacol Ther (1986) 0.91
Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation (1982) 0.91
Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations. J Pharm Sci (1988) 0.89
The effect of butoxamine on catecholamine-induced metabolic changes in humans. Clin Pharmacol Ther (1966) 0.87
Acute toxicity of benzene inhalation to hemopoietic precursor cells. Toxicol Appl Pharmacol (1977) 0.87
The influence of age on dorsal hand vein responsiveness to norepinephrine. Clin Pharmacol Ther (1986) 0.87
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet (1983) 0.87
Toxicity of a hepatotoxic laxative preparation in tissue culture and excretion in bile in man. Clin Pharmacol Ther (1972) 0.86
Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther (1972) 0.86
Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol (1990) 0.86
Simplified liquid-chromatographic assay of amiodarone and desethylamiodarone after solid-phase extraction. Clin Chem (1986) 0.86
Digoxin therapy during T-tube biliary drainage in man. JAMA (1978) 0.86
Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism (1968) 0.86
Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Arch Int Pharmacodyn Ther (1978) 0.85
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J (1976) 0.85
Creatinine elevation in patients receiving amiodarone correlates with serum amiodarone concentration. Br J Clin Pharmacol (1993) 0.85
Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin Pharmacol Ther (1974) 0.85